Results 1 to 10 of about 393 (166)

Antioxidant Compounds in the Treatment of Alzheimer's Disease: Natural, Hybrid, and Synthetic Products. [PDF]

open access: yesEvid Based Complement Alternat Med, 2023
Alzheimer’s disease (AD) which is associated with cognitive dysfunction and memory lapse has become a health concern. Various targets and pathways have been involved in AD’s progress, such as deficit of acetylcholine (ACh), oxidative stress, inflammation, β‐amyloid (Aβ) deposits, and biometal dyshomeostasis.
Hatami M   +5 more
europepmc   +2 more sources

Design, synthesis, and characterization of (1-(4-aryl)-1H-1,2,3-triazol-4-yl)methyl, substituted phenyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates against Mycobacterium tuberculosis

open access: yesDrug Design, Development and Therapy, 2016
Katharigatta N Venugopala,1,2 G B Dharma Rao,3 Subhrajyoti Bhandary,3 Melendhran Pillay,4 Deepak Chopra,3 Bandar E Aldhubiab,1 Mahesh Attimarad,1 Osama Ibrahim Alwassil,1 Sree Harsha,1 Koleka Mlisana4 1Department of Pharmaceutical Sciences, College of ...
Venugopala KN   +9 more
doaj  

Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives. [PDF]

open access: yesFront Endocrinol (Lausanne), 2022
Ilyas U   +7 more
europepmc   +1 more source

Synthesis of 3,4-Dihydropyrimidin(thio)one Containing Scaffold: Biginelli-like Reactions. [PDF]

open access: yesPharmaceuticals (Basel), 2022
Sánchez-Sancho F   +6 more
europepmc   +1 more source

Mesoporous molecular sieve MCM-41 catalyzed one-pot synthesis of 3,4-dihydro-2(1H)-pyrimidinones and –thiones under solvent-free conditions

open access: yesBulletin of the Chemical Society of Ethiopia, 2011
An efficient synthesis of 3,4-dihydro-2(1H)-pyrimidinones and -thiones using MCM-41 as the catalyst from an aldehyde, β-keto ester, and urea or thiourea under solvent-free conditions is described.
Rahim Hekmatshoar   +3 more
doaj  

Home - About - Disclaimer - Privacy